C8orf42 Inhibitors
C8orf42 inhibitors encompass a range of chemical compounds that act on specific signaling pathways, with the end result being a decrease in C8orf42 activity. The primary pathways targeted by these inhibitors include the PI3K/AKT, JNK, p38 MAPK, and MEK/ERK pathways. A majority of these compounds, such as resveratrol, LY294002, quercetin, genistein, wortmannin, apigenin, and EGCG, act on the PI3K/AKT pathway, a critical signaling pathway that C8orf42 is thought to interact with. By inhibiting this pathway, these compounds can effectively reduce the functional activity of C8orf42.
Other inhibitors target different but related pathways. For example, curcumin and SP600125 hinder the JNK and p38 MAPK pathways. Simultaneously, SB203580 acts on the p38 MAPK pathway, and PD98059 and U0126 inhibit the MAPK and MEK/ERK pathways, respectively. These pathways are believed to intersect with C8orf42's functional mechanisms. Consequently, these inhibitors can indirectly reduce C8orf42 activity by dampening the signaling pathways it is involved with.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol can inhibit the PI3K/AKT pathway. C8orf42 indirectly interacts with PI3K/AKT, and its inhibition through resveratrol can lead to reduced activity of C8orf42. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin can affect JNK and p38 MAPK signaling pathways. C8orf42 is thought to interact with these pathways, and curcumin's influence can lead to decreased C8orf42 activity. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin has been shown to inhibit the PI3K/AKT pathway. As C8orf42 is known to interact with this pathway, inhibition by quercetin can decrease the activity of C8orf42. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein inhibits the PI3K/AKT pathway. Given C8orf42's interaction with this pathway, its inhibition through genistein can result in reduced C8orf42 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits the p38 MAPK pathway. If C8orf42 interacts with this pathway, its inhibition by SB203580 can lead to decreased C8orf42 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits the JNK pathway. C8orf42, believed to interact with this pathway, can have its function decreased by this inhibition. | ||||||
Apigenin | 520-36-5 | sc-3529 sc-3529A sc-3529B sc-3529C sc-3529D sc-3529E sc-3529F | 5 mg 100 mg 1 g 5 g 25 g 100 g 1 kg | $33.00 $214.00 $734.00 $1151.00 $2348.00 $3127.00 $5208.00 | 22 | |
Apigenin inhibits the PI3K/AKT pathway. C8orf42's interaction with this pathway means its activity can be reduced by apigenin's inhibitory effects. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG can inhibit the PI3K/AKT pathway. C8orf42 indirectly interacts with PI3K/AKT, and its inhibition through EGCG can lead to reduced activity of C8orf42. | ||||||